Praluzatamab provides a CD166-targeting monoclonal antibody for cancer and antibody research. It recognizes CD166, also known as activated leukocyte cell adhesion molecule (ALCAM), a cell-surface protein expressed in various epithelial cancers. Praluzatamab supports studies of tumor antigen recognition, antibody-mediated targeting, and antibody-drug conjugate (ADC) development.
Key Features and Benefits
- CD166-Targeting Antibody: Recognizes CD166/ALCAM, a cell-surface adhesion protein specifically associated with tumor biology and cellular interactions.
- Monoclonal Antibody Design: Provides an antibody platform specifically for investigating CD166 recognition and tumor cell targeting.
- CD166 Recognition: Supports investigation of CD166 expression, antibody binding, internalization, and antigen-specific cellular interactions.
- Tumor Cell Targeting: Enables studies of antibody binding to CD166-expressing cancer cells.
- ADC Development Platform: Provides the antibody component specifically associated with Praluzatamab Ravtansine (CX-2009), an investigational CD166-directed Probody drug conjugate.
- Probody Technology Research: Supports investigation of protease-activated antibody targeting strategies designed to improve tumor-selective activity.
- Cellular Internalization Research: Especially useful for studying antibody uptake and intracellular trafficking in CD166-expressing cells.
- Antibody Engineering Research: Supports investigation of antibody conjugation, antigen specificity, and targeted payload delivery.
Applications
- Breast Cancer Research: Supports investigation of CD166-targeted antibody strategies in breast cancer models.
- Triple-Negative Breast Cancer Research: Useful for studying CD166 expression and antibody-mediated targeting in triple-negative breast cancer models.
- Ovarian Cancer Research: Supports evaluation of CD166-directed targeting strategies in relevant ovarian cancer models.
- CD166-Positive Cancer Research: Useful for investigating antibody recognition and cellular responses in CD166-expressing tumors.
- Tumor Antigen Research: Supports studies of CD166/ALCAM expression and its role in tumor-associated cellular processes.
- ADC Research: Provides an antibody platform for investigating CD166-directed payload conjugation and delivery strategies.
- Probody Drug Conjugate Research: Supports investigation of tumor-associated protease activation and conditional antibody targeting.
- Antibody Binding Assays: Useful for evaluating antigen recognition, binding specificity, and antibody-cell interactions.
- Comparative Antibody Research: Supports comparison of conventional antibodies, conditionally activated antibodies, and CD166-directed targeting strategies.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for monoclonal antibody research materials. Maintain conditions that preserve antibody stability, structural integrity, and antigen-binding activity.
Praluzatamab provides a CD166-directed antibody platform for investigating tumor-associated antigen recognition and targeted cancer cell binding and specifically supports breast cancer, ovarian cancer, CD166-positive tumor, antibody engineering, and ADC research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
